Journal of Neuro-Oncology

, Volume 11, Issue 1, pp 37–41 | Cite as

Hyperthermic potentiation of BCNU toxicity in BCNU-resistant human glioma cells

  • Vasco F. Da Silva
  • Mark Feeley
  • Gijsbert P. Raaphorst
Laboratory Investigations

Summary

Experimental evidence indicating potentiation of the cytotoxic effect of drugs at high temperatures suggests that the utilization of drug-heat combinations for gliomas of the brain might be therapeutically useful. Hyperthermia may increase the cytotoxicity of a particular drug in areas of low drug concentration/time and in cell populations resistant to the drug. We report in vitro experiments with a BCNU resistant, U-373MG, and a BCNU sensitive, U-87MG, human derived glioma cell lines under hyperthermic conditions. Temperatures equal or above 42°C potentiate BCNU cell kill in both lines. The thermo-sensitizer lidocaine increases thermal cell kill but only minimally with concentrations corresponding to therapeutic plasma lidocaine levels. Within our experimental conditions, the best strategy to overcome BCNU resistance involved a combination of heat, BCNU and cis-DDP. BCNU resistant cells have no cross resistance to cis-DDP and the combination of BCNU and cis-DDP is synergystic. At modest hyperthermic conditions (42°C) 99.4% BCNU resistant cells are killed by a combination of BCNU and cis-DDP at drug concentrations identical to plasma concentrations after standard IV doses. Clinical protocols using heat and drug may need to incorporate two or more drugs for optimal effects.

Key words

glioma therapeutic hyperthermia drug resistance BCNU cis-DDP lidocaine 

Abbreviations

BCNU

1,3-bis (2-Chloroethyl)-1-nitrosourea

cis-DDP

Cis-Diamminedichloroplatinum (II)

AZO

Aziridinylbenzoquinone

TER

Thermal Enhancement Ratio

References

  1. 1.
    Rosenblum ML, Gerosa MA: Stem cell sensitivity. Prog Exp Tumor Res 28: 1–17, 1984Google Scholar
  2. 2.
    Levin VA, Landahl HD, Patlak CS: Drug delivery to CNS tumors. Cancer Treat Rep 65 (Suppl 2): 19–25, 1981Google Scholar
  3. 3.
    Rosenblum ML, Gerosa MA, Bodell WJ, Talcott RL: Tumor cell resistance. Prog Exp Tumor Res 27: 191–214, 1984Google Scholar
  4. 4.
    Da Silva VF, Raaphorst GP, Goyal R, Feeley M: Drug cytotoxicity at elevated temperature — in vitro study on the U-87MG glioma cell line. J Neurosurg 67: 885–888, 1987Google Scholar
  5. 5.
    Salcman M: Feasibility of microwave hyperthermia for brain tumor therapy. Prog Exp Tumor Res 280: 220–231, 1984Google Scholar
  6. 6.
    Scudiero DA, Meyer SA, Clatterbuck BE, Mattern MR, Ziolkowski CHJ, Day III RS: Sensitivity of human cell strains having different abilities to repair O6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. Cancer Res 44: 2467–2474, 1984Google Scholar
  7. 7.
    Wallner K, Li GC: Adriamycin resistance, heat resistance and radiation response in Chinese hamster fibroblasts. Int J Radiat Oncol Biol Phys 12: 829–833, 1986Google Scholar
  8. 8.
    Wallner KE, DeGregorio MW, Li GC: Hyperthermic potentiation of cis-diamminedichloroplatinum (II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res 46: 6242–6245, 1986Google Scholar
  9. 9.
    Levin VA, Hoffman W, Weinkam RJ: Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. Cancer Treat Rep 62: 1305–1312, 1978 (5). Salcman M: Feasibility of microwave hyperthermia for brain tumor therapy. Prog Exp Tumor Res 280: 220–231, 1984Google Scholar
  10. 10.
    Wiestler OD, Pegg AE, Kleihues P: Repair of 06-alkylguanine in cellular DNA: significance for tumor induction and chemotherapy. In: Voth D, Krauseneck P (eds) Chemotherapy of Gliomas. De Gruyter, Berlin, 1984, pp 61–69Google Scholar
  11. 11.
    Levin VA, Kabra PM, Freeman-Dove MA: Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. J Neurosurg 48: 587–593, 1978Google Scholar
  12. 12.
    Bigger JT, Hoffman BF: Antiarrythmic drugs. In: Goodman AG, Goodman LS, Rall TW, Murad F (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, ed 7. McMillan, New York, 1985, pp 748–783Google Scholar
  13. 13.
    Casper ES, Kelson DP, Alcock NW, Young CW: Platinum concentrations in bile and plasma following rapid and 6-hour infusions of cis-diamminedichloroplatinum (II). Cancer Treatment Rep 63: 2023–2025, 1979Google Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • Vasco F. Da Silva
    • 1
  • Mark Feeley
    • 2
  • Gijsbert P. Raaphorst
    • 3
  1. 1.Neurosurgery, University of Ottawa, Ottawa Civic HospitalOntario Cancer Treatment and Research FoundationCanada
  2. 2.Ottawa Regional Cancer CentreOntario Cancer Treatment and Research FoundationCanada
  3. 3.Ontario Cancer Treatment and Research FoundationUniversity of OttawaCanada

Personalised recommendations